跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 189 条关于
“CDK12i”
全部
189
临床试验
63
药物
108
机构
0
资讯
18
2年前
Immunotherapy Shows Promise in Prostate Cancer with MMRd Mutation
去年
Insilico Medicine Develops Novel AI-Designed CDK12/13 Inhibitors for Treatment-Resistant Cancers
去年
Carrick Therapeutics Initiates Phase 1 Trial of Novel CDK12/13 Inhibitor CT7439 in Advanced Solid Tumors
去年
Cyclacel Completes Enrollment in Fadraciclib Trial for Tumors with CDKN2A/B Abnormalities
4年前
Junshi Biosciences' Anti-CD112R Monoclonal Antibody, TAB009/JS009, Receives FDA IND Approval for Advanced Solid Tumors
去年
Phase 1/2 Study Reports Final Results for CD123-Targeted Tagraxofusp in Relapsed/Refractory Myelofibrosis
5年前
FDA Lifts Partial Clinical Hold on RVU120 Trial in AML and MDS
去年
CDK1 and TDP1 Inhibition Synergistically Overcomes Cancer Drug Resistance
5个月前
Gilead Exercises Option for Kymera's KT-200 CDK2 Degrader, Triggering $45M Milestone Payment
去年
Gilead and Kymera Partner on Novel CDK2 Molecular Glue Degrader for Cancer Treatment
第 1 页,共 2 页
上一页
下一页